
Millennium Pharmacon International Tbk PT
IDX:SDPC


to continue SDPC research
to continue SDPC research
You've reached your weekly stock limit.
Sign UpMillennium Pharmacon International Tbk PT?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
116
173
|
Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does Millennium Pharmacon International Tbk PT hold over its rivals?
What risks and challenges
does Millennium Pharmacon International Tbk PT face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Millennium Pharmacon International Tbk PT.
Provide an overview of the primary business activities
of Millennium Pharmacon International Tbk PT.
What unique competitive advantages
does Millennium Pharmacon International Tbk PT hold over its rivals?
What risks and challenges
does Millennium Pharmacon International Tbk PT face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Millennium Pharmacon International Tbk PT.
Provide P/S
for Millennium Pharmacon International Tbk PT.
Provide P/E
for Millennium Pharmacon International Tbk PT.
Provide P/OCF
for Millennium Pharmacon International Tbk PT.
Provide P/FCFE
for Millennium Pharmacon International Tbk PT.
Provide P/B
for Millennium Pharmacon International Tbk PT.
Provide EV/S
for Millennium Pharmacon International Tbk PT.
Provide EV/GP
for Millennium Pharmacon International Tbk PT.
Provide EV/EBITDA
for Millennium Pharmacon International Tbk PT.
Provide EV/EBIT
for Millennium Pharmacon International Tbk PT.
Provide EV/OCF
for Millennium Pharmacon International Tbk PT.
Provide EV/FCFF
for Millennium Pharmacon International Tbk PT.
Provide EV/IC
for Millennium Pharmacon International Tbk PT.
Compare the intrinsic valuations
of Millennium Pharmacon International Tbk PT and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Millennium Pharmacon International Tbk PT against its competitors.
Analyze the profit margins
(gross, operating, and net) of Millennium Pharmacon International Tbk PT compared to its peers.
Compare the P/E ratios
of Millennium Pharmacon International Tbk PT against its peers.
Discuss the investment returns and shareholder value creation
comparing Millennium Pharmacon International Tbk PT with its peers.
Analyze the financial leverage
of Millennium Pharmacon International Tbk PT compared to its main competitors.
Show all profitability ratios
for Millennium Pharmacon International Tbk PT.
Provide ROE
for Millennium Pharmacon International Tbk PT.
Provide ROA
for Millennium Pharmacon International Tbk PT.
Provide ROIC
for Millennium Pharmacon International Tbk PT.
Provide ROCE
for Millennium Pharmacon International Tbk PT.
Provide Gross Margin
for Millennium Pharmacon International Tbk PT.
Provide Operating Margin
for Millennium Pharmacon International Tbk PT.
Provide Net Margin
for Millennium Pharmacon International Tbk PT.
Provide FCF Margin
for Millennium Pharmacon International Tbk PT.
Show all solvency ratios
for Millennium Pharmacon International Tbk PT.
Provide D/E Ratio
for Millennium Pharmacon International Tbk PT.
Provide D/A Ratio
for Millennium Pharmacon International Tbk PT.
Provide Interest Coverage Ratio
for Millennium Pharmacon International Tbk PT.
Provide Altman Z-Score Ratio
for Millennium Pharmacon International Tbk PT.
Provide Quick Ratio
for Millennium Pharmacon International Tbk PT.
Provide Current Ratio
for Millennium Pharmacon International Tbk PT.
Provide Cash Ratio
for Millennium Pharmacon International Tbk PT.
What is the historical Revenue growth
over the last 5 years for Millennium Pharmacon International Tbk PT?
What is the historical Net Income growth
over the last 5 years for Millennium Pharmacon International Tbk PT?
What is the current Free Cash Flow
of Millennium Pharmacon International Tbk PT?
Discuss the annual earnings per share (EPS)
trend over the past five years for Millennium Pharmacon International Tbk PT.
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
ID |
![]() |
Millennium Pharmacon International Tbk PT
IDX:SDPC
|
164.3B IDR | 8.8 | |
US |
![]() |
Mckesson Corp
NYSE:MCK
|
89.3B USD | 17.4 |
|
US |
![]() |
Cencora Inc
NYSE:COR
|
57.6B USD | 14.6 |
|
US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
57.5B USD | 14.6 |
|
US |
![]() |
Cardinal Health Inc
NYSE:CAH
|
38.8B USD | 13.5 |
|
AU |
![]() |
Sigma Healthcare Ltd
ASX:SIG
|
32.9B AUD | 1 524.1 |
|
CN |
![]() |
Huadong Medicine Co Ltd
SZSE:000963
|
70.3B CNY | 15.4 |
|
CN |
![]() |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
70.5B CNY | 10.7 |
|
US |
![]() |
Henry Schein Inc
NASDAQ:HSIC
|
9.1B USD | 11 |
|
KR |
![]() |
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 59.9 |
|
AU |
E
|
EBOS Group Ltd
OTC:EBOSY
|
8.2B USD | 30.1 |
|
EBITDA Growth | EV/EBITDA to Growth | |||||
---|---|---|---|---|---|---|
ID |
![]() |
Millennium Pharmacon International Tbk PT
IDX:SDPC
|
Average EV/EBITDA:
156.4
8.8
|
N/A | N/A | |
US |
![]() |
Mckesson Corp
NYSE:MCK
|
17.4
|
15%
|
1.2 |
|
US |
![]() |
Cencora Inc
NYSE:COR
|
14.6
|
10%
|
1.5 |
|
US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
14.6
|
10%
|
1.5 |
|
US |
![]() |
Cardinal Health Inc
NYSE:CAH
|
13.5
|
11%
|
1.2 |
|
AU |
![]() |
Sigma Healthcare Ltd
ASX:SIG
|
1 524.1
|
N/A | N/A |
|
CN |
![]() |
Huadong Medicine Co Ltd
SZSE:000963
|
15.4
|
18%
|
0.9 |
|
CN |
![]() |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
10.7
|
17%
|
0.6 |
|
US |
![]() |
Henry Schein Inc
NASDAQ:HSIC
|
11
|
6%
|
1.8 |
|
KR |
![]() |
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
59.9
|
32%
|
1.9 |
|
AU |
E
|
EBOS Group Ltd
OTC:EBOSY
|
30.1
|
14%
|
2.1 |
|
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.